Established in 2014, Hansi Aitai CNI Biomedicine Index Technology (Wuhan) Co., Ltd. is an innovative biotechnology company focusing on structural biology, translational medicine and clinical development. The company is committed to developing next-generation immunotherapeutics to provide affordable, safe, and efficient medical solutions to patients around the world to meet the challenges of major diseases. Adhering to an innovation-driven mission and vision, Hansatec focuses on discovering, developing and commercializing products for precise treatment of cancer and autoimmune diseases, striving to meet unmet global medical needs, promote disease prevention, control and reduction, and contribute to global health. The company's research and management team has many years of rich experience in European and American new drug research and development, industrialization implementation and management in key national research institutions and multinational pharmaceutical companies. In Wuhan, Hangzhou, Shanghai, Hong Kong, San Diego, and Australia, the company has formed a complete management team from drug discovery to clinical research, and has built a high-affinity, long-half-life antibody screening platform with global patents, and an innovative tumor-targeting Positioning Smallmolecule-Antibody (GPSMAb) technology platform. At present, Hansatec has established an independent innovative drug product pipeline focusing on cancer and immune diseases, and is actively carrying out international cooperation projects to contribute to global health.